Evidence map›Paper›PMID 34725835›Full record

ArticleJournal of applied toxicology : JAT2022

Summary of 17 chemicals evaluated by OECD TG229 using Japanese Medaka, Oryzias latipes in EXTEND 2016.

Yukio Kawashima, Yuta Onishi, Norihisa Tatarazako, Hirotaka Yamamoto, Masaaki Koshio, Tomohiro Oka, Yoshifumi Horie, Haruna Watanabe, Takashi Nakamoto, Jun Yamamoto and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of applied toxicology : JAT, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Yukio KawashimaEnvironmental Consulting Department, Japan NUS Co., Tokyo, Japan.
Yuta OnishiInstitute of Environmental Ecology, IDEA Consultants, Inc., Shizuoka, Japan.
Norihisa TatarazakoDepartment of Science and Technology for Biological Resources and Environment, Graduate School of Agriculture, Ehime University, Matsuyama, Japan.ORCID 0000-0001-7098-8809
Hirotaka YamamotoEnvironmental Consulting Department, Japan NUS Co., Tokyo, Japan.
Masaaki KoshioHealth and Environmental Risk Division, National Institute for Environmental Studies, Tsukuba, Japan.
Tomohiro OkaHealth and Environmental Risk Division, National Institute for Environmental Studies, Tsukuba, Japan.
Yoshifumi HorieHealth and Environmental Risk Division, National Institute for Environmental Studies, Tsukuba, Japan.ORCID 0000-0002-4558-8624
Haruna WatanabeHealth and Environmental Risk Division, National Institute for Environmental Studies, Tsukuba, Japan.
Takashi NakamotoInstitute of Environmental Ecology, IDEA Consultants, Inc., Shizuoka, Japan.
Jun YamamotoInstitute of Environmental Ecology, IDEA Consultants, Inc., Shizuoka, Japan.
Hidenori IshikawaInstitute of Environmental Ecology, IDEA Consultants, Inc., Shizuoka, Japan.
Tomomi SatoNanobioscience Department, Yokohama City University, Yokohama, Japan.
Kunihiko YamazakiEnvironmental Health Department, Ministry of the Environment of Japan, Tokyo, Japan.
Taisen IguchiNanobioscience Department, Yokohama City University, Yokohama, Japan.
Institute for Development and Economic Analysis · IDNational Institute for Environmental Studies · JPEngineering Advancement Association of Japan · JPYokohama City University · JPKobe Pharmaceutical University · JPMinistry of the Environment · JP

Funding

Ministry of the Environment
6 · The paper itself

Abstract

In June 2016, the Ministry of the Environment of Japan announced a program "EXTEND2016" on the implementation of testing and assessment for endocrine active chemicals, consisting of a two-tiered strategy. The aim of the Tier 1 screening and the Tier 2 testing is to identify the impacts on the endocrine system and to characterize the adverse effects to aquatic animals by endocrine disrupting chemicals detected in the aquatic environment in Japan. For the consistent assessment of the effects on reproduction associated with estrogenic, anti-estrogenic, androgenic, and/or anti-androgenic activities of chemicals throughout Tier 1 screening to Tier 2 testing, a unified test species, Japanese medaka (Oryzias latipes), has been used. For Tier 1 screening, the in vivo Fish Short-Term Reproduction Assay (OECD test guideline No. 229) was conducted for 17 chemicals that were nominated based on the results of environmental monitoring, existing knowledge obtained from a literature survey, and positive results in reporter gene assays using the estrogen receptor of Japanese medaka. In the 17 assays using Japanese medaka, adverse effects on reproduction (i.e., reduction in fecundity and/or fertility) were suggested for 10 chemicals, and a significant increase of hepatic vitellogenin in males, indicating estrogenic (estrogen receptor agonistic) potency, was found for eight chemicals at the concentrations in which no overt toxicity was observed. Based on these results, and the frequency and the concentrations detected in the Japanese environment, estrone, 4-nonylphenol (branched isomers), 4-tert-octylphenol, triphenyl phosphate, and bisphenol A were considered as high priority candidate substances for the Tier 2 testing.

Indexed as

Endocrine DisruptorsOryziasWater Pollutants, ChemicalAnimalsMaleOrganisation for Economic Co-Operation and DevelopmentReceptors, EstrogenReproductionVitellogeninsEndocrine DisruptorsReceptors, EstrogenVitellogeninsWater Pollutants, Chemicalendocrine disrupting effectJapanese medakaOECD TG229Oryzias latipesreproduction

Identifiers

PMID34725835
PMCPMC9297976
OpenAlexW3211065945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.